货号:A1209823 同义名: JNJ28871063 hydrochloride
JNJ 28871063 hydrochloride is a selective ErbB receptor family inhibitor with IC50 values of 21, 22 and 38 nM for ErbB4, EGFR and ErbB2 respectively.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | EGFR/ErbB1 ↓ ↑ | ErbB3 ↓ ↑ | ErbB4 ↓ ↑ | HER2/ErbB2 ↓ ↑ | mutant EGFR ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WZ-3146 |
++++
EGFR (E746_A750), IC50: 2 nM EGFR (E746_A750/T790M), IC50: 14 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Daphnetin |
+
EGFR, IC50: 7.67 μM |
PKA,PKC | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Lifirafenib |
++
EGFR, IC50: 29 nM |
+
EGFR(T790M/L858R), IC50: 495 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
PD168393 |
++++
EGFR, IC50: 0.70 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Nazartinib |
++
mutant EGFR, Ki: 0.031 μM |
++
mutant EGFR, Ki: 0.031 μM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Norcantharidin | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
CL-387785 |
++++
EGFR, IC50: 370 pM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
WHI-P154 |
+++
EGFR, IC50: 4 nM |
VEGFR,Src | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Tyrphostin A9 |
+
EGFR, IC50: 460 μM |
PDGFR | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
AG 555 |
+
EGFR, IC50: 0.7 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
AG 494 |
+
EGFR, IC50: 1.2 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
AG-556 |
+
EGFR, IC50: 5 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
RG13022 |
+
EGFR, IC50: 4 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Tyrphostin RG 14620 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Vandetanib |
+
EGFR, IC50: 500 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
CNX-2006 |
++
mutant EGFR, IC50: <20 nM |
++
mutant EGFR, IC50: <20 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
AZD3759 |
++++
EGFR (L858R), IC50: 0.2 nM EGFR (WT), IC50: 0.3 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Erlotinib |
++++
EGFR, IC50: 2 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Saracatinib |
+++
EGFR (L861Q), IC50: 4 nM EGFR, IC50: 5 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
AG1557 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Rociletinib |
++
EGFR (wt), Ki: 303.3 nM EGFR (L858R/T790M), Ki: 21.5 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
AG490 |
+
EGFR, IC50: 0.1 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Cetuximab |
++++
EGFR, Kd: 0.39 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Osimertinib |
++
L858R/T790M EGFR, IC50: 11.44 nM WT EGFR, IC50: 12.92 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Osimertinib mesylate | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Chrysophanol | ✔ | mTOR | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
PD153035 |
++++
EGFR, Ki: 5.2 pM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Olmutinib | ✔ | BTK | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
WZ4002 |
++++
EGFR (L858R), IC50: 2 nM EGFR (L858R/T790M), IC50: 8 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Icotinib |
+++
EGFR, IC50: 5 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Desmethyl Erlotinib HCl |
++++
EGFR, IC50: 2 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Cyasterone | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
PP 3 |
+
EGFR tyrosine kinase, IC50: 2.7 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
WZ8040 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
(-)-Epigallocatechin Gallate | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
AG 18 |
+
EGFR, IC50: 35 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
O-Desmethyl gefitinib |
++
EGFR, IC50: 36 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Falnidamol | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
AZ-5104 |
++++
EGFR (L858R), IC50: 6 nM EGFR (L861Q) , IC50: <1 nM |
+++
ErbB4, IC50: 7 nM |
BRK | {[allProObj[0].p_purity_real_show]} | |||||||||||||||
Butein | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Genistein | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
SU5214 |
+
EGFR, IC50: 36.7 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Naquotinib | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Gefitinib |
++
EGFR, IC50: 15.5 nM |
+
EGFR (858R/T790M), IC50: 823.3 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Theliatinib |
+++
WT EGFR, IC50: 3 nM |
++
EGFR T790M/L858R, IC50: 22 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Lazertinib |
++++
L858R/T790M EGFR, IC50: 2 nM WT EGFR, IC50: 76 nM |
++++
Del19/T790M, IC50: 1.7 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Gefitinib-based PROTAC 3 |
++
EGFR, DC50: 22.3 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
MTX-211 | ✔ | PI3K | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
(E)-AG 99 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Licochalcone D | ✔ | Caspase,PARP | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Zipalertinib |
+++
EGFR WT, IC50: 8 nM EGFR (L861Q), IC50: 4.1 nM |
+++
HER4, IC50: 4 nM |
++++
EGFR L858R, IC50: 2 nM EGFR(d746-750), IC50: 1.4 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
JND3229 |
+++
EGFR WT, IC50: 6.8 nM |
++
EGFR L858R/T790M, IC50: 30.5 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Firmonertinib mesylate | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Tyrphostin AG30 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
EGFR-IN-12 |
++
EGFR, IC50: 21 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Mobocertinib | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
(Rac)-JBJ-04-125-02 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
(S)-Sunvozertinib | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
BLU-945 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Poziotinib |
+++
HER1, IC50: 3.2 nM |
++
HER4, IC50: 23.5 nM |
+++
HER2, IC50: 5.3 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
TAK-285 |
++
EGFR/HER1, IC50: 23 nM |
+
HER4, IC50: 260 nM |
++
HER2, IC50: 17 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
ARRY-380 analog | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Canertinib |
++++
EGFR, IC50: 1.5 nM |
+++
ErbB2, IC50: 9.0 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Dacomitinib |
+++
EGFR, IC50: 6.0 nM |
+
ErbB4, IC50: 73.7 nM |
+
ErbB2, IC50: 45.7 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
EGFR/ErbB-2/ErbB-4 inhibitor-2 |
+
ErbB4, IC50: 1.91 μM |
+
ErbB2, IC50: 0.08 μM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
(E/Z)-CP-724714 |
++
HER2/ErbB2, IC50: 10 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Lapatinib |
++
EGFR, IC50: 10.8 nM |
+
ErbB4, IC50: 367 nM |
+++
ErbB2, IC50: 9.2 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
AEE788 |
++++
EGFR, IC50: 2 nM |
+
HER4/ErbB4, IC50: 160 nM |
+++
HER2/ErbB2, IC50: 6 nM |
c-Fms | {[allProObj[0].p_purity_real_show]} | ||||||||||||||
AV-412 free base |
++++
EGFR, IC50: 0.75 nM |
++
ErbB2, IC50: 19 nM |
++++
EGFRT790M, IC50: 0.79 nM EGFRL858R/T790M, IC50: 0.51 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Neratinib |
+
EGFR, IC50: 92 nM |
+
HER2, IC50: 59 nM |
Src | {[allProObj[0].p_purity_real_show]} | |||||||||||||||
BMS-599626 |
++
HER1, IC50: 20 nM |
+
HER4, IC50: 190 nM |
++
HER2, IC50: 30 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Tucatinib |
+++
ErbB2, IC50: 8 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Allitinib |
++++
EGFR, IC50: 0.5 nM |
++++
ErbB4, IC50: 0.8 nM |
+++
ErbB2, IC50: 3.0 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Pelitinib |
+
EGFR, IC50: 38.5 nM |
+
ErbB2, IC50: 1.255 μM |
Raf,Src | {[allProObj[0].p_purity_real_show]} | |||||||||||||||
Sapitinib |
+++
EGFR, IC50: 4 nM |
+++
ErbB3, IC50: 4 nM |
+++
ErbB2, IC50: 3 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
CUDC-101 |
+++
EGFR, IC50: 2.4 nM |
++
HER2, IC50: 15.7 nM |
HDAC | {[allProObj[0].p_purity_real_show]} | |||||||||||||||
Varlitinib |
+++
ErbB1, IC50: 7 nM |
++++
ErbB2, IC50: 2 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Afatinib dimaleate |
++++
EGFR (wt), IC50: 0.5 nM EGFR (L858R/T790M), IC50: 0.4 nM |
++
HER2, IC50: 14 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Canertinib dihydrochloride |
+++
EGFR, IC50: 7.4 nM |
+++
ErbB2, IC50: 9 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Allitinib tosylate |
++++
EGFR (T790M/L858R), IC50: 12 nM EGFR, IC50: 0.5 nM |
++++
ErbB4, IC50: 0.8 nM |
+++
ErbB2, IC50: 3.0 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Tyrphostin AG 528 |
+
EGFR, IC50: 4.9 μM |
+
HER2, IC50: 2.1 μM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Afatinib |
++++
EGFR (wt), IC50: 0.5 nM EGFR (L858R), IC50: 10 nM |
++++
ErbB4, IC50: 1 nM |
++
HER2, IC50: 14 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Pyrotinib dimaleate |
++
EGFR, IC50: 0.013 μM |
++
HER2, IC50: 0.038 μM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Epertinib HCl |
++++
EGFR, IC50: 1.48 nM |
+++
HER4, IC50: 2.49 nM |
+++
HER2, IC50: 7.15 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Tuxobertinib |
++++
EGFR, Kd: 0.2 nM |
++++
HER2, Kd: 0.76 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
ALK-IN-1 |
++
EGFR(del19), IC50: 36.8 nM EGFR(C797S/del19), IC50: 138.6 nM |
ALK | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Brigatinib |
+
EGFR(del19), IC50: 39.9 nM EGFR(C797S/T790M/del19), IC50: 67.2 nM |
ALK,FLT3 | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Avitinib |
++++
EGFR L858R/T790M, IC50: 0.18 nM |
BTK | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
EAI045 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Almonertinib | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
BI-4020 |
++++
EGFRdel19 T790M C797S, IC50: 0.2 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
EGFR-IN-7 |
++++
EGFRd746-750/T790M/C797S, IC50: 0.26 nM EGFRL858R/T790M, IC50: 0.19 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.93mL 0.39mL 0.19mL |
9.63mL 1.93mL 0.96mL |
19.25mL 3.85mL 1.93mL |
CAS号 | 944342-90-9 |
分子式 | C24H28Cl2N6O3 |
分子量 | 519.423 |
别名 | JNJ28871063 hydrochloride |
运输 | 蓝冰 |
存储条件 |
粉末 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 | |
动物实验配方 |